TRUTAKNA cut kidney progression risk 76%. Why did VERA stock give up a double-digit rally?
TRUTAKNA cuts IgA nephropathy progression risk 76% through two years, but VERA stock reverses as competition and launch execution come into focus.
Pharma & Biotech
Pharma & Biotech
Vera Therapeutics has FDA approval for TRUTAKNA, but the real test comes next
Find out how Vera Therapeutics’ TRUTAKNA approval could reshape IgA nephropathy treatment while key kidney data remain ahead.